Megesin

Megestrol acetate, the active ingredient in Megesin, is a progestin presented as an oral formulation for systemic use. It is employed in hormone therapy to manage cachexia associated with AIDS or cancer, and as part of treatment regimens for certain breast and endometrial cancers.

GNH USA supplies Megesin as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, oncology centres, pharmacies and clinics worldwide. The product meets European Union quality standards and is distributed under strict regulatory oversight.

Megestrol acetate is used in hormone‑related conditions and cancer‑associated cachexia. - Cachexia associated with AIDS or cancer: improves appetite and promotes weight gain. - Breast cancer: used as part of hormonal therapy to inhibit tumor growth. - Endometrial cancer: employed to control disease progression in advanced cases.

Megestrol acetate may cause a range of adverse reactions, which are categorized by frequency and severity.

Common Side Effects: - Weight gain: increased appetite leading to excess caloric intake. - Edema: fluid retention causing swelling of limbs. - Nausea: mild gastrointestinal discomfort. - Fatigue: generalized tiredness.

Serious or Rare Side Effects: - Thromboembolic events: deep vein thrombosis or pulmonary embolism. - Adrenal suppression: reduced endogenous cortisol production. - Hyperglycemia: elevated blood glucose levels, especially in diabetic patients.

When prescribing Megesin, clinicians should consider several safety measures. - Monitor weight: assess for excessive gain or fluid retention. - Evaluate blood glucose: check for hyperglycemia in at‑risk patients. - Assess thrombotic risk: consider prophylaxis in patients with history of clotting. - Review hormonal status: avoid in patients with known hormone‑sensitive tumors unless indicated. - Pregnancy and lactation: contraindicated or use only if benefits outweigh risks; exercise caution. - Store at ambient temperature: keep below 25 °C, retain in original packaging, protect from moisture and light.

Megestrol acetate can interact with several drug classes, requiring careful management.

Major Interactions (Avoid): - Anticoagulants (e.g., warfarin): may increase risk of thrombosis. - CYP3A4 inducers (e.g., rifampin): can reduce plasma levels of megesterol acetate. - Glucocorticoids: additive effects on glucose metabolism and adrenal suppression.

Moderate Interactions (Monitor Closely): - Antidiabetic agents: may require dose adjustment due to hyperglycemia. - Hormonal contraceptives: potential reduction in contraceptive efficacy. - Antifungal azoles (e.g., ketoconazole): may increase megesterol acetate concentrations.